U.S. Stem Cell
Sunrise
About U.S. Stem Cell
US Stem Cell is a biotechnology company engaged in the discovery, development of autologous cell therapies for the treatment of chronic and acute heart damage. Its product includes MyoCell, a clinical therapy designed to populate regions of scar tissue within a patient's heart with autologous muscle cells, or cells from a patient's body, for the purpose of improving cardiac function in chronic heart failure patients. The company's discoveries include multiple cell therapies in various stages of development that repair damaged tissues throughout the body due to injury or disease so that patients may return to a normal lifestyle.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Total funding: $897.0K
- Funding stage: IPO
- Last round: Post-IPO Debt (Feb 2021)
- Ticker: otcpink:USRM
- Website: us-stemcell.com
- Phone: 954-835-1500
Industries & Categories
Biotechnology, Health Care, Professional Services
Social Profiles
Canonical: https://fsome.com/organization/u-s-stem-cell-2215225 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.